Insider Stock Trading History of Hagan Joseph P


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Hagan Joseph P since year 2005. The trader's CIK number is 1465278. At the time of this reporting, Hagan Joseph P is the President and CEO of Regulus Therapeutics Inc. . (stock ticker symbol RGLS). See this page for all insider trading activities at Regulus Therapeutics Inc. .

Note that in the past Hagan Joseph P also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Hagan Joseph P since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-07-25 RGLS Regulus Therapeutics Inc. Buy 219,780 .91 199,999
2016-03-03 RGLS Regulus Therapeutics Inc. Buy 10,000 7.19 71,900
2014-09-15 OREX Orexigen Therapeutics, Inc. Buy 5,000 4.69 23,450
2013-07-31 OREX Orexigen Therapeutics, Inc. Sale 12,000 7.80 93,600
2013-07-31 OREX Orexigen Therapeutics, Inc. Option Ex 12,000 1.66 19,920
2013-07-26 OREX Orexigen Therapeutics, Inc. Option Ex 10,000 1.66 16,600
2013-07-26 OREX Orexigen Therapeutics, Inc. Sale 10,000 7.40 74,000
2013-05-28 OREX Orexigen Therapeutics, Inc. Option Ex 28,000 1.66 46,480
2013-05-28 OREX Orexigen Therapeutics, Inc. Sale 28,000 7.00 196,000
2012-07-13 OREX Orexigen Therapeutics, Inc. Sale 30,000 6.80 204,000
2012-07-13 OREX Orexigen Therapeutics, Inc. Option Ex 30,000 1.66 49,800
2012-06-28 OREX Orexigen Therapeutics, Inc. Sale 26,000 5.90 153,400
2012-06-29 OREX Orexigen Therapeutics, Inc. Sale 12,000 6.30 75,600
2012-06-27 OREX Orexigen Therapeutics, Inc. Option Ex 70,000 1.66 116,200
2012-06-28 OREX Orexigen Therapeutics, Inc. Option Ex 26,000 1.66 43,160
2012-06-27 OREX Orexigen Therapeutics, Inc. Sale 70,000 5.22 365,190
2012-06-29 OREX Orexigen Therapeutics, Inc. Option Ex 12,000 1.66 19,920

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hagan Joseph P (President and CEO of Regulus Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.